Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Colorcon
Harvard Business School
Mallinckrodt
Dow

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-901

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug TAK-901?

TAK-901 is an investigational drug.

There have been 314 clinical trials for TAK-901. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are five US patents protecting this investigational drug and eighty-four international patents.

Recent Clinical Trials for TAK-901
TitleSponsorPhase
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1
A Study of TAK-994 in Participants With Narcolepsy Type 1TakedaPhase 1
Intratumoral Microdosing of TAK-981 in Head and Neck CancerTakedaEarly Phase 1

See all TAK-901 clinical trials

Clinical Trial Summary for TAK-901

Top disease conditions for TAK-901
Top clinical trial sponsors for TAK-901

See all TAK-901 clinical trials

US Patents for TAK-901

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-901   Start Trial Use of small molecules to enhance MAFA expression in pancreatic endocrine cells Janssen Biotech, Inc. (Horsham, PA)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-901

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-901 Argentina 100446 2034-05-16   Start Trial
TAK-901 Australia 2015259573 2034-05-16   Start Trial
TAK-901 Canada 2949056 2034-05-16   Start Trial
TAK-901 China 106414720 2034-05-16   Start Trial
TAK-901 European Patent Office 3143127 2034-05-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Express Scripts
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.